News
Foghorn Therapeutics halts FHD-286 development for AML, focusing on proprietary pipeline and Lilly collaboration; strong cash position until 2027. Quiver AI Summary Foghorn Therapeutics announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback